Abington Neurological Associates, Ltd.

Abington, Pennsylvania 19001

0 studies enrolling now · 14 studies all time

What they study most

Advancing Multiple Sclerosis, Alzheimer Disease, Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment, Dementia, Idiopathic Hypersomnia, Lewy Body Dementia Psychosis, Mild Cognitive Impairment (MCI), Multiple Sclerosis, Narcolepsy

Studies at this site

• Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — Recruiting now
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy — Completed
• A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy — Completed
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) — Completed
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• Escitalopram for Agitation in Alzheimer's Disease — Running, not enrolling
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed